Treatment with Vyndaqel (tafamidis) reduces signs of heart damage for most people with hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM) associated with the A97S mutation,…
ATTR-CM
Eidos Therapeutics announced that the Phase 3 clinical trial evaluating its lead candidate acoramidis (formerly known as AG10) in treating adults with transthyretin amyloidosis cardiomyopathy (ATTR-CM)…
Recent Posts
- Approval of Beyonttra in Brazil brings new treatment options for ATTR-CM
- Real-world Amvuttra safety signals mostly match known profile
- FDA puts ATTR-CM therapy candidate coramitug on fast track
- Wainua shows similar benefits for men, women with hATTR-PN in trial
- The challenges of adapting to life with chronic illness for patient and caregiver